Table 2 Pharmacological treatment
From: Outcome in juvenile idiopathic arthritis: a population-based study from Sweden
Total | ERA | Oligoarticular | RF− | RF+ | JPsA | sJIA | uJIA | ||
|---|---|---|---|---|---|---|---|---|---|
Extended | Persistent | ||||||||
No treatment | 109 (43.4) | 6 (27.3) | 13 (46.4) | 49 (58.3) | 11 (31.4) | 4 (23.5) | 7 (41.2) | 5 (71.4) | 14 (34.1) |
NSAID | 246 (98.0) | 22 (100) | 27 (96.4) | 83 (98.8) | 35 (100) | 16 (94.1) | 17 (100) | 7 (100) | 39 (95.1) |
Oral glucocorticoids | 107 (42.6) | 11 (50) | 14 (50) | 12 (14.3) | 21 (60) | 14 (82.4) | 7 (41.2) | 5 (71.4) | 23 (56.1) |
Intra-articular steroids* | 198 (78.9) | 16 (72.7) | 25 (89.3) | 69 (82.1) | 25 (71.4) | 15 (88.2) | 11 (64.7) | 3 (42.9) | 34 (82.9) |
cDMARDs | 163 (64.9) | 17 (77.3) | 25 (89.3) | 27 (32.1) | 32 (91.4) | 17 (100) | 12 (70.6) | 2 (28.6) | 32 (78.0) |
bDMARD | 60 (23.9) | 7 (31.8) | 11 (39.2) | 3 (3.6) | 13 (37.1) | 12 (70.6) | 2 (11.8) | 1 (14.3) | 11 (26.8) |
TNFα inhibitor + methotrexate | 52 (20.7) | 4 (18.2) | 11 (39.2) | 1 (1.2) | 13 (37.1) | 12 (70.6) | 2 (11.8) | 1 (14.3) | 8 (19.5) |